Skip to content

US · TCMD · MEDICAL - DEVICES

Tactile Systems Technology, Inc. (TCMD) intrinsic value and stock valuation

$25.60as of 2026-11-21 · Mkt cap 676.24M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tactile Systems Technology, Inc. DCF and intrinsic value

InvestorsCraft values TCMD with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from TCMD’s statements →

Tactile Systems Technology, Inc. Graham Number

Graham Number: $13.41d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Minneapolis, MN 55416 tactilemedical.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$329.5M+12% 5y CAGRd
20132025
Net income
$19.1M
20132025
Free cash flow
$40.4M+140.7% 5y CAGRd
20132025
Total equity
$218.9M+11.9% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$329.5M$293M$274.4M$246.8M$208.1M
Operating income$29.3M$22.2M$18M-$-12.76M-$-1.76M
Net income$19.1M$17M$28.5M-$-17.87M-$-11.81M
EPSd$819.3K$702.6K$1.23M-$-890.38K-$-598.88K
Operating cash flow$42.8M$40.7M$35.9M$5.21M$2.63M
Capital expenditure-$-2.38M-$-2.51M-$-2.48M-$-1.92M-$-2.35M
Free cash flow$40.4M$38.2M$33.4M$3.29M$280K
Total assets$273.9M$297.9M$281.4M$255M$244.3M
Total debt$16M$45.1M$50.4M$72.2M$80.6M
Net debt-$-67.49M-$-49.26M-$-10.66M$50.3M$52.4M
Total equity$218.9M$216.6M$193.6M$121.4M$128.2M
Cash and short-term investments$83.5M$108.9M$75.2M$38.1M$40.7M
Income statement
20252024202320222021
Revenue$329.5M$293M$274.4M$246.8M$208.1M
Cost of revenue$81.8M$76.3M$79.3M$70.8M$59.8M
Gross profit$247.7M$216.7M$195.1M$176M$148.2M
Research and development expenses$8.48M$8.83M$7.82M$7.09M$5.66M
Selling, general and administrative expenses$209.9M$183.1M$169.2M$167.2M$143.6M
Other expenses$0.00$2.53M$80K$14.4M$740K
Operating expenses$218.4M$194.5M$177.1M$188.7M$150M
Cost and expenses$300.2M$270.8M$256.4M$259.5M$209.8M
Interest income$3.1M$3.38M$1.87M$60K$0.00
Interest expense$1.04M$2.08M$4.15M$2.79M$0.00
Depreciation and amortization$6.64M$6.8M$6.5M$14.4M$3.68M
Ebitda$39M$32.4M$26.4M$1.75M$1.39M
Operating income$29.3M$22.2M$18M-$-12.76M-$-1.76M
Total other income/expenses, net$2.06M$1.31M-$-2.27M-$-2.71M-$-530K
Income before tax$31.3M$23.5M$15.8M-$-15.47M-$-2.29M
Income tax expense$12.3M$6.53M-$-12.74M$2.39M$9.52M
Net income$19.1M$17M$28.5M-$-17.87M-$-11.81M
Weighted average shares outstanding$22.9M$23.9M$22.9M$20.1M$19.7M
Weighted average diluted shares outstanding$23.3M$24.1M$23.2M$20.1M$19.7M
Balance sheet
20252024202320222021
Cash and short-term investments$83.5M$108.9M$75.2M$38.1M$40.7M
Net receivables$43.9M$44.9M$43.2M$54.8M$49.5M
Inventory$14M$18.7M$22.5M$23.1M$19.2M
Total current assets$165.2M$177.6M$145.3M$119.8M$113.6M
Property, plant and equipment, net$18.9M$22.2M$25.3M$27.4M$30.7M
Goodwill and intangible assets$70.2M$73.9M$77.8M$81.4M$85.1M
Long-term investments$300K$0.00$0.00$0.00$0.00
Total non-current assets$108.8M$120.4M$136.1M$135.2M$130.7M
Total assets$273.9M$297.9M$281.4M$255M$244.3M
Accounts payable$4.97M$5.65M$6.66M$9.98M$5.02M
Short-term debt$3.19M$5.94M$5.76M$5.47M$5.47M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$41M$40.7M$41.1M$64.3M$34.5M
Long-term debt$12.8M$39.2M$44.6M$66.8M$75.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$14.1M$40.6M$46.7M$69.3M$81.6M
Capital lease obligations$3.19M$18.9M$21.2M$23.4M$25.9M
Total liabilities$55M$81.3M$87.8M$133.6M$116M
Common stock$20K$20K$20K$20K$20K
Retained earnings$54.9M$35.9M$18.9M-$-9.62M$8.24M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$218.9M$216.6M$193.6M$121.4M$128.2M
Total investments$300K$14.5M$14.2M$16.1M$12.5M
Total debt$16M$45.1M$50.4M$72.2M$80.6M
Net debt-$-67.49M-$-49.26M-$-10.66M$50.3M$52.4M
Cash flow statement
20252024202320222021
Net income$19.1M$17M$28.5M-$-17.87M-$-11.81M
Depreciation and amortization$6.64M$6.8M$6.5M$6.27M$3.7M
Stock-based compensation$8.36M$7.82M$7.55M$9.6M$10.2M
Change in working capital$120K$7.71M$15.1M-$-4.63M-$-9.46M
Accounts receivable-$-150K$9.17M$23.8M-$-15.56M-$-9.04M
Inventory$4.64M$3.86M$600K-$-3.91M$970K
Accounts payable-$-760K-$-1.09M-$-3.85M$4.96M$830K
Net cash provided by operating activities$42.8M$40.7M$35.9M$5.21M$2.63M
Investments in property, plant and equipment-$-2.38M-$-2.39M-$-2.32M-$-1.78M-$-2.1M
Acquisitions, net$0.00$0.00$0.00$0.00-$-79.83M
Net cash used for investing activities-$-2.54M-$-2.5M-$-2.48M-$-1.91M-$-82.18M
Common stock issued$1.61M$0.00$34.6M$0.00$6.29M
Common stock repurchased-$-26.56M-$-3.51M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-51.2M-$-4.82M$5.73M-$-9.6M$59.9M
Net change in cash-$-10.92M$33.3M$39.1M-$-6.3M-$-19.63M
Cash at end of period$83.5M$94.4M$61M$21.9M$28.2M
Operating cash flow$42.8M$40.7M$35.9M$5.21M$2.63M
Capital expenditure-$-2.38M-$-2.51M-$-2.48M-$-1.92M-$-2.35M
Free cash flow$40.4M$38.2M$33.4M$3.29M$280K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tactile Systems Technology, Inc.

        Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compression device designed for managing lymphedema. The company also offers the Entre system, a portable pneumatic compression solution for at-home treatment of various venous disorders, including lymphedema, chronic venous insufficiency, and venous leg ulcers. Additionally, Tactile Systems provides the AffloVest, a portable high-frequency chest wall oscillation device used to address retained pulmonary secretions associated with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Established in 1995, the company maintains its headquarters in Minneapolis, Minnesota.

        CEO
        Sheri Louise Dodd
        Employees
        1.09K
        Beta
        0.79

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Tactile Systems Technology, Inc. (TCMD)?

        Tactile Systems Technology, Inc. (TCMD) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TCMD undervalued?

        TCMD trades at a price of $25.60 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.